These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 22101116

  • 1. Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
    Klein RJ, Hallden C, Gupta A, Savage CJ, Dahlin A, Bjartell A, Manjer J, Scardino PT, Ulmert D, Wallström P, Vickers AJ, Lilja H.
    Eur Urol; 2012 Mar; 61(3):471-7. PubMed ID: 22101116
    [Abstract] [Full Text] [Related]

  • 2. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [Abstract] [Full Text] [Related]

  • 3. Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
    Li W, Middha M, Bicak M, Sjoberg DD, Vertosick E, Dahlin A, Häggström C, Hallmans G, Rönn AC, Stattin P, Melander O, Ulmert D, Lilja H, Klein RJ.
    Eur Urol; 2018 Dec; 74(6):710-719. PubMed ID: 30289108
    [Abstract] [Full Text] [Related]

  • 4. Replication study of 34 common SNPs associated with prostate cancer in the Romanian population.
    Jinga V, Csiki IE, Manolescu A, Iordache P, Mates IN, Radavoi D, Rascu S, Badescu D, Badea P, Mates D.
    J Cell Mol Med; 2016 Apr; 20(4):594-600. PubMed ID: 26773531
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
    Ulmert D, Cronin AM, Björk T, O'Brien MF, Scardino PT, Eastham JA, Becker C, Berglund G, Vickers AJ, Lilja H.
    BMC Med; 2008 Feb 15; 6():6. PubMed ID: 18279502
    [Abstract] [Full Text] [Related]

  • 6. The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.
    Möller A, Olsson H, Grönberg H, Eklund M, Aly M, Nordström T.
    Prostate Cancer Prostatic Dis; 2019 Mar 15; 22(1):137-142. PubMed ID: 30171228
    [Abstract] [Full Text] [Related]

  • 7. Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels.
    Li W, Bicak M, Sjoberg DD, Vertosick E, Dahlin A, Melander O, Ulmert D, Lilja H, Klein RJ.
    Prostate; 2020 Dec 15; 80(16):1405-1412. PubMed ID: 32914890
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
    Nordström T, Aly M, Eklund M, Egevad L, Grönberg H.
    Eur Urol; 2014 Jun 15; 65(6):1184-90. PubMed ID: 23891454
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
    Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, Bjartell AS, Scardino PT, Ulmert D, Vickers AJ.
    Cancer; 2011 Mar 15; 117(6):1210-9. PubMed ID: 20960520
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Sjoberg DD, Vickers AJ, Assel M, Dahlin A, Poon BY, Ulmert D, Lilja H.
    Eur Urol; 2018 Jun 15; 73(6):941-948. PubMed ID: 29519548
    [Abstract] [Full Text] [Related]

  • 14. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Assel M, Dahlin A, Ulmert D, Bergh A, Stattin P, Lilja H, Vickers AJ.
    Eur Urol; 2018 Jun 15; 73(6):961-967. PubMed ID: 29066048
    [Abstract] [Full Text] [Related]

  • 15. Genetic predisposition to early recurrence in clinically localized prostate cancer.
    Borque Á, del Amo J, Esteban LM, Ars E, Hernández C, Planas J, Arruza A, Llarena R, Palou J, Herranz F, Raventós CX, Tejedor D, Artieda M, Simon L, Martínez A, Carceller E, Suárez M, Allué M, Sanz G, Morote J.
    BJU Int; 2013 Apr 15; 111(4):549-58. PubMed ID: 22759231
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Profile of common prostate cancer risk variants in an unscreened Romanian population.
    Iordache PD, Mates D, Gunnarsson B, Eggertsson HP, Sulem P, Guðmundsson J, Benónísdóttir S, Csiki IE, Rascu S, Radavoi D, Ursu R, Staicu C, Calota V, Voinoiu A, Jinga M, Rosoga G, Danau R, Sima SC, Badescu D, Suciu N, Radoi V, Manolescu A, Rafnar T, Halldórsson BV, Jinga V, Stefánsson K.
    J Cell Mol Med; 2018 Mar 15; 22(3):1574-1582. PubMed ID: 29266682
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
    Choi SY, Kim HJ, Cheong HS, Myung SC.
    Korean J Urol; 2015 Jan 15; 56(1):19-30. PubMed ID: 25598933
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.